-65%

est. 2Y upside i

FinTechHealthcareSeries A

Truemed is redefining how Americans use their healthcare dollars. We partner with leading health and wellness brands — including Peloton, Garmin, Sleep Number, and many more — to make their products eligible for HSA/FSA spending. The result: a simple, affordable way for consumers to invest in tools that actually improve their health.

Rank

#985

Sector

Fintech, Healthtech, Wellness

Est. Liquidity

~5Y

Data Quality

Data: Medium

Truemed is a high-growth (3x YoY revenue) Series A company in a promising niche, enabling HSA/FSA payments for preventive health.

Last updated: March 10, 2026

Bull (30%)+300%

Truemed successfully expands its network of merchant partners to thousands more, becoming the de facto standard for HSA/FSA payments in preventive health. Aggressive market penetration and new regulatory clarity for wellness spending drive revenue to over $200M by 2028, justifying an $800M+ valuation at 4x current valuation.

Base (40%)+50%

Truemed continues its strong growth, maintaining its niche in the HSA/FSA wellness market. It fends off smaller competitors and sees moderate adoption by new brands. Revenue reaches approximately $100M by 2028, leading to a $300M valuation, representing a solid but not explosive return.

Bear (30%)-75%

Large incumbent HSA/FSA administrators or payment processors (e.g., HealthEquity, Optum Financial) launch directly competing, well-funded solutions that leverage their existing customer bases and regulatory expertise. This commoditizes Truemed's offering, leading to slowed growth, pricing pressure, and a down round to $50M, significantly eroding common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $34M in liquidation preferences, representing 17% of the assumed $200M post-money valuation. In an exit at or below $34M, common stock holders would receive nothing.

Dilution Risk

high

As a Series A company, Truemed will likely require multiple additional funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

Given its early stage, there are currently no active secondary markets or tender offers for Truemed equity, limiting early liquidity options.

Go to Market — 4 roles

Operations — 1 role

Product & Design — 1 role

View all 6 open roles at Truemed →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Truemed's data — designed to show you've done your homework.

  • 1

    “Given the high regulatory barrier and the importance of Letters of Medical Necessity, how does Truemed plan to scale its compliance and clinical review processes efficiently while maintaining strict adherence to IRS guidelines?”

  • 2

    “With large incumbents like HealthEquity and Optum Financial in the HSA/FSA administration space, what is Truemed's long-term strategy to maintain its competitive differentiation and prevent these players from replicating or acquiring its core offering?”

  • 3

    “Considering the Series A funding and the typical timeline for venture-backed companies, how is Truemed thinking about a liquidity event timeline for employees, and what key milestones are critical to achieving that within a 5-7 year horizon?”

Community

Valuation Sentiment

Our model estimates -65% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.